Skip to main content

Ongoing FDAEvent 99459 (2 months ago)

FilmArray NGDS Warrior Panel

The FilmArray NGDS Warrior Panel has mismatches between the outbreak strain and the reference strain used in its development.

Moderate risk

Using it may cause temporary or medically reversible health problems. Serious harm is unlikely.

FDA Class II recall · How risk is rated

What to do

What happened

Biofire Defense of Salt Lake City, Utah, is recalling its FilmArray NGDS Warrior Panel REF NGDS-ASY-0007, a qualitative, multiplexed, nucleic acid-based in vitro diagnostic test intended for use with the FilmArray 2.0 system, because the firm has identified mismatches between the outbreak strain and the reference strain used in the development of the panel.

The test detects and identifies Bacillus anthracis, Yersinia pestis, Francisella tularensis, Coxiella burnetii, Ebola virus, and Marburg virus nucleic acids directly from human whole blood (EDTA).

The recall began July 16, 2026, and was added to the FDA's Enforcement Report on August 4, 2026. The product was distributed nationwide in the states of AL, CA, DC, FL, GA, HI, KY, LA, MA, MD, MN, NC, NH, NV, NY, OH, RI, TN, TX, UT, VA and WA. The recall covers 122 kits (3,660 pouches).

Summary by Recall Canary from the FDA notice.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medical device recalls:

  1. A device recall doesn't always mean you must stop using it: it may need to be checked, adjusted or fixed.
  2. Talk to your health care provider before you stop using it.

Is yours affected?

Match the UDI-DI and lot code listed under your product.

  1. FilmArray NGDS Warrior Panel REF NGDS-ASY-0007 UDI-DI code: (01)00851458005136 The

    UDI-DI
    • 00851458005136
    Lot
    • 311825D
    • 312025D
    • 313526D
    • 322925D

Details

Company began the recall
Event ID
99459
Recall No.
Z-2877-2026
Company
Biofire DefenseSalt Lake City, Utah
Quantity recalled
122 kits (3,660 pouches)
Recall type
Voluntary: Firm initiated
Customers told by
Letter
  1. Company began the recall

  2. Added to FDA's Enforcement Report · Classified by FDA

  3. Listed on Recall Canary

  4. In FDA's weekly enforcement report

  5. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 2, 2026 · primary source: U.S. Food and Drug Administration